Rekah Pharmaceutical Industry Ltd (REKA) - Total Assets

Latest as of December 2025: ILA423.68 Million ILA ≈ $1.14 Million USD

Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) holds total assets worth ILA423.68 Million ILA (≈ $1.14 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Rekah Pharmaceutical Industry Ltd book value and equity for net asset value and shareholders' equity analysis.

Rekah Pharmaceutical Industry Ltd - Total Assets Trend (2004–2025)

This chart illustrates how Rekah Pharmaceutical Industry Ltd's total assets have evolved over time, based on quarterly financial data.

Rekah Pharmaceutical Industry Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Rekah Pharmaceutical Industry Ltd's total assets of ILA423.68 Million consist of 54.9% current assets and 45.1% non-current assets.

Asset Category	Amount (ILA)	% of Total Assets
Cash & Equivalents	ILA0.00	1.0%
Accounts Receivable	ILA135.40 Million	32.0%
Inventory	ILA91.22 Million	21.5%
Property, Plant & Equipment	ILA0.00	0.0%
Intangible Assets	ILA56.27 Million	13.3%
Goodwill	ILA0.00	0.0%

Asset Composition Trend (2004–2025)

This chart illustrates how Rekah Pharmaceutical Industry Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Rekah Pharmaceutical Industry Ltd (REKA) market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Rekah Pharmaceutical Industry Ltd's current assets represent 54.9% of total assets in 2025, an increase from 0.0% in 2004.
Cash Position: Cash and equivalents constituted 1.0% of total assets in 2025, down from 1.2% in 2004.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 2.0% in 2004.
Asset Diversification: The largest asset category is accounts receivable at 32.0% of total assets.

Rekah Pharmaceutical Industry Ltd Competitors by Total Assets

Key competitors of Rekah Pharmaceutical Industry Ltd based on total assets are shown below.

Company	Country	Total Assets
GALDERMA GROUP AG NYSE:GALDY	USA	$13.39 Billion
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	China	CN¥16.53 Billion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt F:RIG2	Germany	€1.60 Trillion
Kangmei Pharmaceutical Co Ltd SHG:600518	China	CN¥13.68 Billion
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	China	CN¥10.21 Billion
Shandong Lukang Pharmaceutical Co Ltd SHG:600789	China	CN¥9.88 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion
Hunan Warrant Pharmaceutical Co. Ltd. A SHG:688799	China	CN¥2.53 Billion

Rekah Pharmaceutical Industry Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	1.53	1.45	2.06
Quick Ratio	0.93	0.93	1.19
Cash Ratio	0.00	0.00	0.00
Working Capital	ILA80.82 Million	ILA71.01 Million	ILA112.05 Million

Rekah Pharmaceutical Industry Ltd - Advanced Valuation Insights

This section examines the relationship between Rekah Pharmaceutical Industry Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	0.88
Latest Market Cap to Assets Ratio	0.08
Asset Growth Rate (YoY)	-5.3%
Total Assets	ILA423.68 Million
Market Capitalization	$33.57 Million USD

Valuation Analysis

Below Book Valuation: The market values Rekah Pharmaceutical Industry Ltd's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Rekah Pharmaceutical Industry Ltd's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Rekah Pharmaceutical Industry Ltd (2004–2025)

The table below shows the annual total assets of Rekah Pharmaceutical Industry Ltd from 2004 to 2025.

Year	Total Assets	Change
2025-12-31	ILA423.68 Million ≈ $1.14 Million	-5.26%
2024-12-31	ILA447.22 Million ≈ $1.20 Million	-7.74%
2023-12-31	ILA484.72 Million ≈ $1.30 Million	+8.10%
2022-12-31	ILA448.42 Million ≈ $1.20 Million	+2.59%
2021-12-31	ILA437.09 Million ≈ $1.17 Million	+4.15%
2020-12-31	ILA419.69 Million ≈ $1.13 Million	+14.32%
2019-12-31	ILA367.11 Million ≈ $984.21K	+22.26%
2018-12-31	ILA300.28 Million ≈ $805.04K	+1.81%
2017-12-31	ILA294.95 Million ≈ $790.76K	-8.61%
2016-12-31	ILA322.72 Million ≈ $865.21K	-0.34%
2015-12-31	ILA323.82 Million ≈ $868.16K	+4.42%
2014-12-31	ILA310.11 Million ≈ $831.40K	+2.29%
2013-12-31	ILA303.16 Million ≈ $812.76K	+1.71%
2012-12-31	ILA298.07 Million ≈ $799.11K	+3.86%
2011-12-31	ILA286.99 Million ≈ $769.40K	-0.34%
2010-12-31	ILA287.97 Million ≈ $772.03K	+3.44%
2009-12-31	ILA278.40 Million ≈ $746.38K	-4.16%
2008-12-31	ILA290.50 Million ≈ $778.82K	-3.48%
2007-12-31	ILA300.96 Million ≈ $806.87K	+1.49%
2006-12-31	ILA296.53 Million ≈ $794.99K	+11.06%
2005-12-31	ILA267.00 Million ≈ $715.80K	+32.15%
2004-12-31	ILA202.04 Million ≈ $541.66K	--

About Rekah Pharmaceutical Industry Ltd

TA:REKA Israel Drug Manufacturers - Specialty & Generic

Market Cap

$33.57 Million

ILA12.52 Billion ILA

Market Cap Rank

#23441 Global

#334 in Israel

Share Price

ILA1097.00

Change (1 day)

+2.24%

52-Week Range

ILA1050.00 - ILA1388.00

All Time High

ILA3846.55